Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bigtime! Could not wait.
The company chosen by the university is GB Sciences!!!
BATON ROUGE – LSU has requested its board of supervisors to approve the university to enter into a contract with a company to produce medical marijuana.
The company chosen by the university is GB Sciences, Inc.
Seven businesses, including GB Sciences, Inc. submitted offers to produce medical marijuana for Louisiana through LSU. The marijauana growing operation is estimated to cost $10 million and will be paid by the contractor.
"We're looking for somebody who will be able to provide the quality product for the patients in Louisiana who will be using the medical marijuana product," Dr. Ted Gauthier, LSU professor, told WBRZ News 2 in February
The marijuana will be grown in a facility that will be located off LSU's campus and no students are to be involved. When LSU officially enters into an agreement with GB Sciences, the location of the facility will not be released by the university.
The first crop of medical marijuana is expected to be ready by the end of the year.
http://www.wbrz.com/news/lsu-to-enter-into-contract-with-company-to-grow-medical-marijuana
LSU will name medical marijuana vendor on Thursday 6/22/17
The LSU AgCenter is expected to announced Thursday which vendor it has selected to run its medical marijuana program.
Ashley W. Mullens, an AgCenter spokesperson, declined to divulge the vendor’s name, but seven companies bid for the contract to make products like tinctures, oils, powders and capsules derived from the marijuana plant. The LSU Board of Supervisors will take up the contract at its June 22 meeting.
Gov. John Bel Edwards last year signed legislation that set in motion a functional medical marijuana program, a process that is expected to take at least 18 months. The drug should be available to patients in Louisiana by late 2017 or early 2018, according to LSU officials.
Both LSU and Southern University are contracting with private companies to produce the drug, and 10 distributors throughout the state will be allowed to sell it. LSU’s facility will be in an undisclosed, secured location.
Southern University is slightly behind LSU’s timeline. Janana Snowden, director of the Southern Institute for Medicinal Plants, says the school will have a contract signed by August or September.
“We’re looking to begin a contract in August,” Snowden says. “Once that contract begins … we hope (the vendor) can do it as soon as possible.”
Mullens declined to say whether LSU’s program will be operational by the end of this year, deferring instead to pending statement.
Louisiana has one of the most restrictive medical marijuana programs in the country, allowing only patients with a handful of serious diseases—like cancer and muscular dystrophy—access to the drug.
The state also prohibits the drug in smokeable forms, and LSU AgCenter officials have said they will remove the component of the plant that produces a high.
Columbia Care Louisiana, CB Medica, GB Sciences Louisiana, Citiva LA, Southern Roots Therapeutics, Fourrier House and Terah Holdings applied to be LSU’s partner for the program. The pool was narrowed to two finalists, but Mullens declined to name the companies or say when the decision was made.
https://www.businessreport.com/article/lsu-will-name-medical-marijuana-vendor-thursday
Look inside "1" of GB Science grow rooms!
https://m.facebook.com/gbsciencesinc/photos/a.1060683874063590.1073741830.427189244079726/1073879216077389/?type=3&source=48
As medical marijuana gains........
"this development-stage company develops proprietary technologies that it intends to implement through state-level partners." Hmmmmm
As medical marijuana gains more acceptance, many companies are now participating not only in distributing the product, but also in research and development to improve the production chain. GrowBlox Sciences, Inc is a company that offers solutions for cultivating and processing medical cannabis. Based in Las Vegas, Nevada, this development-stage company develops proprietary technologies that it intends to implement through state-level partners.
A primary technology of GrowBlox Sciences is the GrowBlox Cannabis Grow Chamber. It is an indoor plant-growing chamber with controlled climate and environmental parameters. Another is the InCUBEator Cannabis Propagation Chamber, which is used to ensure consistency in the tissue culture method of cannabis cultivation.
For the extraction of medicinal cannabis compounds, GrowBlox Sciences has ConversionLAB. It uses CO2 to help ensure that the extract is clean. In the final process of drying and curing, the company uses the CureBLOX Cannabis Drying System, which follows a specific algorithm for temperature and humidity. This makes the curing process and the product pathogen-free.
GrowBlox Sciences also presents itself as a leader in processing state and local licenses where there are medical cannabis programs. The company has specialists who cover standard application requests like compliance, security, branding, packaging, and sales plans.
Founded in 2001, GrowBlox Sciences, Inc started out as Flagstick Ventures, Inc. It became the Diabetic Treatment Centers of America, Inc in 2004, then Signature Exploration and Production Corp in 2008. Finally, it changed to GrowBlox Sciences, Inc in April 2014.
The company, valued at USD 22.41 M, currently trades in the OTC markets as GBLX. Its key executives are Craig M. Ellins, CEO and Chairman; Steven W. Weldon, CFO and Chief Accounting Officer; and Dr. Andrea Small-Howard, Chief Science Officer.
http://www.greenrushreview.com/growblox-sciences/
Your numbers are not quite right.
1 mil @ .11 = $110000.00
Spinoff 700 to 1 1428 shares.
Qmkr guesstimate 9 to 1 merger 12852 shares.
$110000.00 ÷ 12852 $8.55 pps break even.
The Apothecary by GB Sciences
7251 Lake Mead Blvd, Suite 300
Las Vegas, NV 89128
Phone: 844-843-2569
Email: info@gbsciences.com
https://headshopfinder.com/head-shop.php?id=19490
Video with Leslie Bocskor of Electrum Partners
http://www.cannabisfn.com/itl/leslie-bocskor-of-electrum-partners/
GB Sciences, Announces Mr. Leslie Bocskor As Vice Chairman.
http://www.prnewswire.com/news-releases/gb-sciences-inc-announces-the-appointment-of-mr-leslie-bocskor-as-vice-chairman-300461103.html
NEW - What activities are permitted without the need for a licence or authorization?
There are activities with industrial hemp to which the CDSA and the IHR do not apply, meaning that they are permitted for anyone without the need for a licence or authorization.
Non-viable Cannabis seeds, bare mature stalks and the fiber derived from these stalks are excluded from the CDSA and from the IHR. This means that these seeds, stalks and fibers can be imported, sold, or used to make products, such as food or rope, without requiring any licence, permit or authorization.
In addition, when certain conditions are met, a person may import, export, sell (at wholesale or retail), provide, possess, transport, send and deliver derivatives of industrial hemp seed, viable grain or non-viable Cannabis seed, or products made from such derivatives, without the need for a licence or authorization under the IHR. The conditions to be met include that the derivative or product:
Must contain no more than 10 µg/g THC;
Must not have been made from whole industrial hemp plants, including sprouts, or the leaves, flowers, or bracts of those plants;
In the case of the wholesale sale of a derivative, the package containing the derivative must be labelled "Contains 10 µg/g THC or less - Contient au plus 10 µg/g de THC".
Note that producing (e.g., cultivating, harvesting) industrial hemp in accordance with the IHR always requires a licence.
http://www.hc-sc.gc.ca/hc-ps/substancontrol/hemp-chanvre/about-apropos/faq/index-eng.php#a34
04/27/17 LSU Vice President said contractor will be selected within the next three to four weeks.
https://m.bestofneworleans.com/thelatest/archives/2017/04/27/plans-to-grow-medical-marijuana-discussed-in-louisiana-house-committee
7 Marijuana Penny Stocks to Watch in June.
For investors who understand the risk and have patience, marijuana penny stocks offer some of the biggest potential profits today.
For example, shares of Medical Cannabis Payment Solutions (OTCMKTS: REFG) have climbed 71.3% in the last 12 months. Shares of OrganiGram Holdings Inc. (OTCMKTS: OGRMF) have done even better, skyrocketing 105.45% over the last 12 months.
In comparison, the Dow Jones Industrial Average is only up 18.07%.
To help investors find these explosive profits, we're giving you a list of marijuana stocks to watch in June.
However, investing in marijuana penny stocks should be treated as speculative right now because cannabis is still illegal under federal law.
marijuana penny stocksAlso, penny stocks are known to have volatile price swings, and most pot stocks trade on over-the-counter markets that aren't regulated like the Nasdaq or NYSE. The stocks on our list are speculative, too – not official recommendations.
These seven companies have recently launched new products, opened stores, conducted research and development, or made important announcements that could lead to an increase in sales.
Here are the seven pot stocks on our radar right now:
Company Stock Symbol Price as of May 31
Digipath Inc. DIGP $0.19
Earth Science Tech Inc. ETST $0.90
GB Sciences Inc. GBLX $0.28
Kaya Holdings Inc. KAYS $0.17
Lexaria Bioscience Corp. LXRP $0.37
Signal Bay Inc. SGBY $0.02
Weed Inc. BUDZ $0.62
Marijuana Penny Stocks to Watch, No. 5: GB Sciences Inc.
On May 23, medical marijuana researcher GB Sciences Inc. (OTCMKTS: GBLX) announced it was filing a patent application for chronic pain and heart therapies.
GB Science's pain solutions are free of THC, the psychoactive component of cannabis, which would limit potential abuse and make it more attractive as a medical solution.
In its May 23 press release, the company also said its novel heart disease formulations would compete in the $316 billion U.S. heart therapy market.
Shares of GBLX closed at $0.28 per share on May 31 and are down 16.05% so far in 2017.
https://moneymorning.com/2017/06/01/7-marijuana-penny-stocks-to-watch-in-june/
New Patent Application for Chronic Pain Therapy
By Staff.
A company called GB Sciences announced the filing of a patent for the treatment of chronic pain based on myrcene-containing complex mixtures (“MCCM”).
The company states that its chronic pain formulations are substantially free of delta-9 tetrahydrocannabinol (“THC”), which minimizes their potential for abuse.
It’s a long way from a patent application to clinical trials and any data showing efficacy or safety of treatments for chronic pain.
Our current drug discovery efforts were accelerated through the combination of proprietary in silico prediction approach, high-throughput screening techniques using cell-based models,” the company stated in a press release. “The current provisional patent application covers myrcene-containing complex mixtures capable of targeting the non-traditional cannabinoid receptor, TRPV1. Our latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016,” the release further stated.
“Many cannabis researchers have theorized that the role of terpenes in cannabis-based therapies is to act as so-called ‘Entourage’ components. We show that the TRPV1 receptor is a target for these ‘Entourage’ compounds, a molecular interaction that had previously been demonstrated for several of the cannabinoids,” said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc.
“We have demonstrated that beta-myrcene is the most significant of several terpenes derived from the cannabis plant that are capable of activating the TRPV1 receptor. Myrcene, like capsaicin, causes TRPV1 desensitization after prolonged exposure, and should therefore prove useful in treating chronic pain. In creating our novel MCCM mixtures for pain, we have also demonstrated that other terpenes and cannabinoids present in the complex mixture, including those that do not demonstrate significant TRPV1 agonist activity on their own, act in combination to increase the efficacy of myrcene. Unlike other pain medications, we leverage molecular synergies among cannabis-plant compounds to target multiple receptors within pain-sensing neural bundles to increase their combined effectiveness at pain relief.”
“These new chronic pain and heart formulas adhere to GB Science’s strategy of commercializing complex mixtures of cannabis-derived compounds whose pharmaceutical activity does not require THC. Instead, the purified THC is sold as a certified raw ingredient or used in co-branded dispensary products,” said John Poss, Chairman and CEO of the company.
http://nationalpainreport.com/new-patent-application-for-chronic-pain-therapy-8833674.html
Marijuana Medication: Hope or Hype?
May 31, 2017
By Pat Anson, Editor
A Las Vegas company that is developing a new cannabis-based treatment for chronic pain has lost money since its inception and there is “substantial doubt” about its ability to survive, according to reports filed with the Securities and Exchange Commission (SEC).
But don’t give up on GB Sciences just yet, says its new chairman and CEO.
“We’re not as financially lame as you might suspect,” John Poss told PNN. “We’ve really done some interesting and groundbreaking research into cannabis.”
Last week GB Sciences issued a press release touting an application by its subsidiary, Growblox Life Sciences, for a patent on new treatments for chronic pain and heart conditions. The company claims to be developing “novel pain formulations” that are substantially free of delta-9 tetrahydrocannabinol (THC), the psychoactive ingredient in cannabis.
"These new chronic pain and heart formulas adhere to GB Science's strategy of commercializing complex mixtures of cannabis-derived compounds whose pharmaceutical activity does not require THC,” Poss said in the news release.
But a review of GB Sciences’ most recent quarterly report with the SEC could raise some doubts among pain patients and investors about whether the company has the resources to develop a cannabis medication. At the end of 2016, GB Sciences had no revenue and over $28 million in debt and liabilities.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern,” the quarterly report says.
But Poss maintains GB Sciences turned a corner in March after raising $9 million from investors. A marijuana grow facility in Las Vegas has also come on line and will soon be producing revenue. Poss thinks the company will be breakeven in cash flow by early next year and could launch a small pilot study of its cannabis medication.
“Either we have something or we don’t. And we’ll find out within a year. If we have something or at least a strong indication that we have something, then our ability to raise money to do a formal clinical trial is greatly enhanced,” said Poss, who hopes to eventually partner GB Sciences with another larger company.
“Before we make bold statements about spending $100 million, we need to spend half a million and find out if it works, which not everyone can do. And we can do that.”
GB Sciences’ stock (GBLX) trades on the over-the-counter “Pink Sheet” market for about 26 cents a share. Historically, the company paid its executives, creditors, and partners with millions of new shares, stock options and warrants, which diluted the value of existing shares. It also gave the company a reputation as a “pump and dump” operation, which Poss says he is working hard to change.
https://www.painnewsnetwork.org/stories/2017/5/31/marijuana-medication-hope-or-hype
GB Sciences files patent for chronic pain & heart therapies.
https://www.gurufocus.com/news/523850/gb-sciences-files-patent-application-for-chronic-pain-and-heart-therapies
GB Sciences, Announces Mr. Leslie Bocskor As Vice Chairman.
http://www.prnewswire.com/news-releases/gb-sciences-inc-announces-the-appointment-of-mr-leslie-bocskor-as-vice-chairman-300461103.html
Nevada MMJ dispensaries begin selling to all adults.
https://www.marijuanatimes.org/nevada-medical-marijuana-dispensaries-to-begin-selling-to-all-adults-this-summer/
Agree Skaark, also people are finding out recreational marijuana goes on sale in Nevada July 1st 2017 and we are growing and expanding in Nevada & expect to have California license this year. Imo
GB Sciences Updated their website.
http://gbsciences.com/
Video: CEO Mr Poss makes 1st Harvest cut.
https://mma.prnewswire.com/media/512129/GB_Sciences_Harvest.mp4
GB Sciences First Las Vegas Harvest!
https://www.benzinga.com/pressreleases/17/05/n9471053/gb-sciences-celebrates-their-first-las-vegas-harvest
GB Sciences, Announces the retirement Chairman and Chief Innovation Officer, Craig Ellins.
https://www.benzinga.com/pressreleases/17/05/n9425073/gb-sciences-revered-founder-craig-ellins-retires
2017 cannabis market developments.
http://www.prnewswire.com/news-releases/2017-cannabis-market-developments-621298583.html
Cannabis cbd vape products see uptick.
http://www.prnewswire.com/news-releases/cannabis-cbd-vape-products-see-uptick-in-sales-in-thriving-legal-marijuana-markets-621145613.html
GB Sciences surpasses key corporate milestones.
http://www.einnews.com/pr_news/378941428/gb-sciences-surpasses-key-corporate-milestones-plus-exclusive-ceo-interview-cfn-media
Leslie Bocskor, Board of directors of GB Sciences
http://finance.yahoo.com/news/mentor-capital-invests-second-tranche-142200869.html
Gb sciences inc could be ready for its next leg up
https://streetregister.com/2017/04/28/gb-sciences-inc-otcmktsgblx-could-be-ready-for-its-next-leg-up/
My Scottrade acct shows Day high and Low .31/.25
Also its harvest time around a week away.
Yes great new video today from GB Sciences.
https://www.facebook.com/gbsciencesinc/videos/1042070282591616/
I feel this stock is still under the radar. Not many people know about it. I think after PR of 1st harvest in 7 to 10 days people will take notice. Imo.GLTA
GB Sciences Partners with Kush Cups.
GB Sciences Partners with Kush Cups
Infused Kush Cups
How do I delete my own posts?